Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 08:08:04 06/02/2026 GMT			5-day change	1st Jan Change
22.94 ^HKD	-0.78%		-1.55%	-5.13%

12-02	3SBio Seeks HK$3.12 Billion via Share Sale	MT
12-02	3SBio to place 105.2 million shares	RE

Press Releases

01/09/25	3SBio : 2025 Interim Results Presentation	PU
30/04/25	3SBio : 2024 ESG Report	PU
25/03/25	3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value	PU
25/03/25	3SBio : 2024 Annual Results	PU
21/01/25	3SBio : 2025 43rd Annual J.P. Morgan Healthcare Conference Corporate Presentation	PU
30/09/24	3SBio : 2024 Interim Report	PU
21/08/24	3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase	PU
25/08/23	3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	PR
24/08/23	3SBio : 2023 Interim Results Presentation	PU
28/04/23	3SBio : 2022 ESG Report	PU
22/03/23	3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%	PR
24/08/22	3SBio : 2022 Interim Results Presentation	PU
24/06/22	3SBio : 1530.HK) _ Prospectus	PU
24/05/22	3SBio : 2021 ESG Report	PU
29/04/22	3SBio : 2021Annual Report	PU
30/03/22	3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses	PU
28/03/22	3SBIO : 2021Annual Results	PU
21/12/21	3SBio : Documents on Display	PU
26/08/21	3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development	PU
30/03/21	3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth	PU
26/02/21	3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020	PU
14/12/20	3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration	PU
23/11/20	3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212	PR
14/09/20	3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China	PU
14/09/20	3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

3SBio stock surges after acquiring licensing rights to cancer drug

March 21, 2025 at 06:49 am